|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.50 USD | +0.09% |
|
-.--% | +159.10% |
| 06-16 | Assertio Holdings Completes Merger With Zydus Lifesciences | MT |
| 06-16 | Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 112M | 158M | 152M | 123M | 119M | |||||
Other Revenues, Total | -985K | -1.29M | 185K | 2.1M | - | |||||
Total Revenues | 111M | 156M | 152M | 125M | 119M | |||||
Cost of Goods Sold, Total | 15.23M | 17.95M | 27.02M | 39.23M | 35.38M | |||||
Gross Profit | 95.78M | 138M | 125M | 85.73M | 83.33M | |||||
Selling General & Admin Expenses, Total | 47.63M | 48.1M | 69.74M | 76.95M | 69M | |||||
R&D Expenses | - | - | 2.84M | 3.82M | 1.69M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 28.11M | 32.61M | 27.53M | 25.64M | 29.86M | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Other Operating Expenses, Total | 75.75M | 80.71M | 100M | 106M | 101M | |||||
Operating Income | 20.04M | 57.57M | 24.94M | -20.68M | -17.22M | |||||
Interest Expense, Total | -10.22M | -7.96M | -3.38M | -3.04M | -3.08M | |||||
Interest And Investment Income | - | - | - | 3.22M | 2.66M | |||||
Net Interest Expenses | -10.22M | -7.96M | -3.38M | 182K | -410K | |||||
Other Non Operating Income (Expenses) | 834K | -960K | -7.14M | 2.76M | 180K | |||||
EBT, Excl. Unusual Items | 10.65M | 48.65M | 14.42M | -17.74M | -17.45M | |||||
Restructuring Charges | -1.09M | - | -5.48M | -720K | -2.89M | |||||
Merger & Related Restructuring Charges | -600K | -800K | -8.9M | - | - | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | -8.17M | |||||
Asset Writedown | - | - | -280M | -5.22M | -1.7M | |||||
In Process R&D Expenses | - | - | - | - | - | |||||
Insurance Settlements | 5M | 2M | - | 1.9M | - | |||||
Legal Settlements | -10.6M | - | - | - | - | |||||
Other Unusual Items | -3.91M | -18.69M | 25.54M | 244K | 276K | |||||
EBT, Incl. Unusual Items | -553K | 31.17M | -254M | -21.53M | -29.94M | |||||
Income Tax Expense | 728K | -78.46M | 77.89M | 52K | 435K | |||||
Earnings From Continuing Operations | -1.28M | 110M | -332M | -21.58M | -30.38M | |||||
Net Income to Company | -1.28M | 110M | -332M | -21.58M | -30.38M | |||||
Net Income - (IS) | -1.28M | 110M | -332M | -21.58M | -30.38M | |||||
Net Income to Common Incl Extra Items | -1.28M | 110M | -332M | -21.58M | -30.38M | |||||
Net Income to Common Excl. Extra Items | -1.28M | 110M | -332M | -21.58M | -30.38M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.45 | 34.98 | -70.1 | -3.4 | -4.74 | |||||
Basic EPS - Continuing Operations | -0.45 | 34.98 | -70.1 | -3.4 | -4.74 | |||||
Basic Weighted Average Shares Outstanding | 2.88M | 3.13M | 4.74M | 6.35M | 6.4M | |||||
Net EPS - Diluted | -0.45 | 30.51 | -70.1 | -3.45 | -4.74 | |||||
Diluted EPS - Continuing Operations | -0.45 | 30.51 | -70.1 | -3.45 | -4.74 | |||||
Diluted Weighted Average Shares Outstanding | 2.88M | 3.64M | 4.74M | 6.35M | 6.4M | |||||
Normalized Basic EPS | 2.31 | 9.7 | 1.9 | -1.75 | -1.7 | |||||
Normalized Diluted EPS | 2.31 | 8.34 | 1.9 | -1.75 | -1.7 | |||||
Supplemental Items | ||||||||||
EBITDA | 49.11M | 90.97M | 53.17M | 5.15M | 12.78M | |||||
EBITA | 48.15M | 90.18M | 52.47M | 4.96M | 12.64M | |||||
EBIT | 20.04M | 57.57M | 24.94M | -20.68M | -17.22M | |||||
EBITDAR | 48.86M | 90.45M | 53.4M | 5.4M | 13.02M | |||||
Total Revenues (As Reported) | 111M | 156M | 152M | 125M | 119M | |||||
Effective Tax Rate - (Ratio) | -131.65 | -251.75 | -30.66 | -0.24 | -1.45 | |||||
Current Domestic Taxes | 511K | 1.92M | 1.69M | 52K | 435K | |||||
Total Current Taxes | 511K | 1.92M | 1.69M | 52K | 435K | |||||
Deferred Domestic Taxes | 217K | -80.38M | 76.2M | - | - | |||||
Total Deferred Taxes | 217K | -80.38M | 76.2M | - | - | |||||
Normalized Net Income | 6.66M | 30.41M | 9.01M | -11.08M | -10.91M | |||||
Interest on Long-Term Debt | 10.22M | 7.96M | 3.38M | 3.04M | 3.08M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 1.8M | 3.4M | 4.4M | 1.8M | 1.3M | |||||
Selling and Marketing Expenses | 1.8M | 3.4M | 4.4M | 1.8M | 1.3M | |||||
Research And Development Expense From Footnotes | - | - | 2.84M | 3.82M | 1.69M | |||||
Net Rental Expense, Total | -250K | -524K | 229K | 256K | 241K | |||||
Imputed Operating Lease Interest Expense | -247K | -466K | 114K | 153K | 147K | |||||
Imputed Operating Lease Depreciation | -2.94K | -57.72K | 115K | 103K | 93.74K | |||||
Stock-Based Comp., COGS (Total) | - | - | - | - | - | |||||
Stock-Based Comp., R&D Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., SG&A Exp. (Total) | 3.54M | 7.5M | 9.16M | 5.01M | 3.45M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 3.54M | 7.5M | 9.16M | 5.01M | 3.45M |
- Stock Market
- Stocks
- ASRT Stock
- Financials Assertio Holdings
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















